The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

Lexaria Bioscience (LEXX) provides the following glucagon-like peptide-1 industry update. It is no surprise that Novo Nordisk’s ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Originally intended as a treatment for diabetes, GLP-1 drugs like Ozempic could be set to turn the food and drink industry ...

The new menu includes five smoothies “created to assist the millions of Americans currently taking prescription GLP-1 medications" Sabrina Weiss is the Editorial Assistant of PEOPLE's food ...

Skelton, MD, professor of pediatrics at Wake Forest University School of Medicine, Winston-Salem, North Carolina, told ...

HealthDay News — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

ETNB has a solid financial runway but faces risks from GLP-1 data and competition within the FGF21 space, making it a Hold ...